Analgina (Sodium Metamizole) is commonly used to help with analgesia, supporting symptomatic relief for moderate to severe pain that creates significant discomfort or interferes with daily function. This is generally relevant across conditions presenting with acute or disruptive episodes, such as post-operative pain, pain following major injury, severe headache, and intense toothache.

The medication is considered relevant for easing symptoms related to spasm-related pain, which is commonly used across conditions characterized by periods of heightened symptoms, easing acute, intense manifestations characteristic of renal or biliary colic and severe dysmenorrhea by addressing symptoms related to heightened physiological activity. The medication is also applied across domains where additional symptomatic support is needed, such as antipyresis, used for managing high fever (pyrexia) that is persistent or those symptoms that have been difficult to tolerate. This range of applications offers supportive relief that may help improve day-to-day comfort during symptomatic periods.

---

Therapeutic Focus: Symptom Domains The primary therapeutic domains include supportive relief for severe pain, managing fever, and addressing spasm-related pain.

---

Regulatory References

1. European Medicines Agency (EMA) on Metamizole Use

Eligibility and Contraindications

Official regulatory documents establish strict criteria for who can and cannot use Analgina (metamizole). The medicine is contraindicated and must not be used by individuals in several specific categories due to serious risks documented in official government labeling.

Classification	Non-Eligible Populations (Contraindications)
Prior History	Previous agranulocytosis caused by metamizole or other pyrazolones/pyrazolidines.
Physiological Status	Third trimester of pregnancy (due to risk of fetal renal impairment and effects on the ductus arteriosus).
Hereditary Conditions	Acute intermittent hepatic porphyria or congenital glucose-6-phosphate-dehydrogenase ( G6PD) deficiency.
Organ/System Health	Impaired bone marrow function or diseases of the hematopoietic system.
Immune Sensitivity	Known hypersensitivity to metamizole and related substances, or analgesic-induced asthma syndrome.

For lactation, repeated use is generally not recommended/contraindicated as significant amounts of the drug's metabolites pass into breast milk; a single dose may require discarding breast milk for a period (e.g., 48 hours). In the pediatric population, use is usually restricted to infants ge 3 months or ge 5 kg; specific fixed-dose forms are not recommended for younger children where accurate weight-based dosing is necessary. Elderly patients and those with existing renal or hepatic impairment may require special consideration, and multiple high doses should be avoided.

Interactions with other medicines and products

Metamizole (Analgina) has documented interactions with several drug classes, requiring specific regulatory restrictions or monitoring. The primary concern areas involve pharmacokinetic effects on co-administered medications and increased risk of additive toxic effects.

Documented Pharmacokinetic Interactions

Metamizole's main active metabolite is a moderate inducer of CYP3A4 and CYP2B6 enzymes. This induction can lead to a reduction in the plasma concentrations and efficacy of co-administered drugs that are sensitive substrates of these enzymes, including Efavirenz, Bupropion, Methadone, and Valproate. Concomitant use with Cyclosporine leads to significantly decreased blood concentrations of the immunosuppressant, requiring therapeutic drug monitoring and potential dose adjustment of Cyclosporine.

Documented Pharmacodynamic and Safety Interactions

Interacting Product Category	Regulatory Constraint or Requirement
Methotrexate	Contraindicated if Methotrexate dose is 15 mg/ week due to high risk of severe hematological toxicity (e.g., bone marrow suppression).
Acetylsalicylic Acid (ASA)	For patients receiving ASA for cardioprotection, co-administration must be carefully managed. Metamizole should be taken at least 30 minutes after or 6 hours before the ASA dose to avoid reducing ASA's antiplatelet effect.
Chlorpromazine	Concomitant use is associated with a risk of severe hypothermia.

These restrictions define the boundaries for safe co-administration, requiring avoidance of certain combinations or mandatory laboratory monitoring for others.

Central Suppression of Nociceptive and Thermoregulatory Signals

The drug's active metabolites function as inhibitors of Cyclooxygenase-3 ( COX-3), an enzyme primarily located in the central nervous system (CNS). This biochemical action reduces the synthesis of Prostaglandin E2 ( PGE2) in the brain and spinal cord. This cascade leads to the suppression of nociceptive signal transmission and the reduction of an elevated hypothalamic temperature set point.

Modulation of Intrinsic Inhibitory Pathways

Metabolites also act as a modulator of the CB1 cannabinoid receptor and stimulate the release of endogenous opioid peptides within the CNS. By augmenting the activity of descending inhibitory pain pathways, this mechanism modulates nociceptive signal propagation via multiple, distinct central mechanisms.

NO-Mediated Visceral Muscle Relaxation

Metabolites influence smooth muscle contractility through the L-arginine/Nitric Oxide ( NO)/cGMP pathway. Activation of this cascade reduces muscle contractility, resulting in the relaxation of involuntary, visceral muscle.

Metamizole (Analgina) is administered via multiple routes to suit different clinical needs, including oral forms (tablets, drops), rectal forms (suppositories), and parenteral forms (intravenous and intramuscular injection). The established usage pattern is short-term and intermittent for acute symptom management, as it is not intended for long-term daily use.

---

Dosing and Frequency Principles

Standard adult dosing is typically limited to a single administration of up to 1,000 mg. The maximum daily dose for oral use generally does not exceed 4,000 mg (4 grams). Dosing should occur up to four times per day, strictly maintaining a minimum interval of 6 to 8 hours between successive doses. Oral administration is commonly taken irrespective of meals (with or without food).

---

Special Administration Requirements

Specific procedural rules govern the use of the injectable solution. Intravenous injection must be performed very slowly, with the rate specified not to exceed 50 mg per minute. This technical constraint is mandatory for proper administration in monitored settings. Furthermore, dosing requires population-specific adjustments; older adults and patients with renal or hepatic impairment are required to use lower doses or have their dosing interval extended to account for slower clearance of the medication's metabolites. Dosing for pediatric patients is primarily determined based on body weight (mg/kg).

Research evidence / Overview of Studies for Analgina (Sodium Metamizole)

---

The Research Basis for Analgina in Acute and Post-Operative Pain Relief

Analgin (Sodium Metamizole) was studied for use in conditions associated with acute or disruptive episodes where there is a need for research exploring how symptoms change over time. The research in this area is characterized by a high volume of studies, relying heavily on short-term Randomized Controlled Trials (RCTs) and comprehensive reviews. Studies primarily included adult populations who were receiving treatment in clinical settings.

The outcomes related to physical discomfort that were measured included changes in symptom intensity as reported by patients and data related to the use of supplemental pain treatment. Findings describe patterns observed in these short-term symptom changes, often focusing on the change observed immediately after a single dose or during a very brief course of treatment. Follow-up durations were typically limited to the initial hours or days of symptom monitoring.

---

Studies on Analgina for Colic and Spasm-Related Pain

Analgin was evaluated in studies for conditions where pain is associated with periods of heightened symptoms related to muscle spasm, such as renal or biliary colic. Researchers examined changes in reported pain intensity, the time to the reported cessation of the acute episode, and the necessity for any additional pain treatments. Evidence so far indicates the studies monitored responses over defined time intervals, with a strong focus on the immediate monitoring of symptoms.

What remains uncertain is the role of this agent in extended treatment scenarios for conditions like colic. Comparative evidence against some alternative treatments for smooth muscle spasm is lacking in the most recent high-quality trials, and the structure of current data reflects short-term monitoring only.

---

Research Examining Analgina's Role in Fever Reduction (Antipyresis)

Research has explored Analgina as an agent in studies examining high body temperature, or pyrexia. Studies were conducted using Randomized Controlled Trials and clinical trials, often comparing Analgina's performance as measured against other common fever-reducing agents. The key outcomes monitored were measurements related to changes in body temperature and the duration of the observed temperature change.

---

Key Limitations and Areas of Uncertainty in the Analgina Evidence

There is limited information for long-term data across nearly all indications, meaning information regarding outcomes beyond the acute treatment phase is limited. Evidence quality varies across studies, with some older reports having methodological constraints. Data for specific subgroups, such as pediatric subjects for persistent fever or the elderly, remains insufficient compared to the general adult population.

Common questions about Analgina (FAQ)

---

Q: What types of pain is Analgina most commonly used for?

Official product information describes the use of Analgina for pain of various origins. This includes treatment for acute pain, post-operative pain, and pain associated with spastic conditions, such as those that affect the digestive tract.

---

Q: Does Analgina also have anti-inflammatory properties?

Yes, official medical literature lists metamizole, the active ingredient in Analgina, as an agent possessing analgesic (pain-relieving), antipyretic (fever-reducing), and anti-inflammatory properties.

---

Q: How quickly does Analgina start working after taking it?

Official product information states a noticeable effect for oral use is typically reported between 30 and 60 minutes after administration. For injection, a clear effect is described as being observed after approximately 30 minutes.

---

Q: How long does the effect of Analgina typically last?

Regulatory guidelines for dosing define the minimum interval required between successive administrations as 6 to 8 hours for adults. This interval provides context for the typical duration of the effect expected from a single dose.

---

Q: Are there known interactions between Analgina and heart medications?

Official documents specifically address co-administration with Acetylsalicylic Acid (ASA) when used for cardioprotection (such as preventing heart attack or stroke). Management is required to ensure Analgina does not reduce the antiplatelet effect of the ASA.

---

Q: Is Analgina considered a type of opioid or narcotic?

No. Analgina (Metamizole) is officially classified by health authorities as a potent non-opioid analgesic and an antipyretic agent.

---

Q: Can Analgina cause stomach upset or digestive issues?

Authoritative safety information indicates that gastrointestinal issues have been observed among reported adverse effects. These have included symptoms such as nausea and vomiting.

---

Q: What kind of research has been done on the long-term use of Analgina?

Official evidence overviews indicate that information regarding outcomes beyond the acute treatment phase is limited, and long-term data is considered insufficient across nearly all indications.

---

Q: Is Analgina banned in the United States?

Yes. The U.S. Food and Drug Administration (FDA) withdrew the approval for Metamizole products due to safety concerns. The drug is currently not available for human use in the United States.

---

Q: What are people usually referring to when they mention 'Analgin reaction'?

The most serious adverse reaction that regulatory authorities focus on is the very rare risk of agranulocytosis. This is a sudden, sharp decrease in white blood cells that compromises the body’s ability to fight infection.

---

Q: What are the signs of a serious reaction to Analgina that people should be aware of?

Official documents describe signs that may indicate the serious adverse reaction agranulocytosis. These signs include fever, chills, a sore throat, or painful sores appearing in the mouth, nose, throat, or genital regions.

---

Q: What is the difference between Analgina and aspirin?

Analgin (Metamizole) is chemically classified as a pyrazolone derivative and is a non-opioid analgesic. In contrast, Acetylsalicylic Acid (Aspirin) is classified as a non-steroidal anti-inflammatory drug (NSAID), which is a different chemical class.

---

Q: Is Analgina available over the counter in all countries where it is sold?

No. The regulation and availability of Metamizole vary significantly across countries. While it is sold over-the-counter in some regions, it is available only by prescription in others.

---

Q: Are there ongoing studies looking into the safety profile of Analgina?

The European Medicines Agency (EMA) has initiated an ongoing review of Metamizole’s risk of agranulocytosis to assess its impact on the current benefit-risk balance.

---

Q: Is Analgina used to treat muscle spasms?

Official documents note that one of the drug's actions is the relaxation of involuntary, visceral muscle, and it is described as being applied in the therapy of spastic conditions.

---

Q: What precautions are mentioned in official documents for people with asthma using Analgina?

Regulatory documents state that Analgina is contraindicated, meaning it must not be used, by individuals who have a prior history of analgesic-induced asthma syndrome.

---

Q: Is Analgina used in veterinary medicine?

Metamizole (Analgin) is a widely used pharmacological substance in both human and veterinary medicine.

---

Q: Are there any specific organs that Analgina is known to impact, aside from the blood?

Regulatory text notes risks related to the blood, such as impaired bone marrow function. It also specifies a risk of fetal renal impairment (kidney damage to the fetus) if the drug is used during the third trimester of pregnancy.

---

Q: Can Analgina be used to reduce inflammation in joints?

The drug is officially listed as possessing anti-inflammatory properties. However, its primary therapeutic purpose as described by regulatory agencies is for pain relief and fever reduction.

---

Q: Is it normal to feel slightly dizzy after taking Analgina?

Dizziness, also referred to as vertigo, is listed among the common adverse events associated with the use of Metamizole.

---

Q: Are there variations in how Analgina is regulated internationally?

Regulation and legal status of Metamizole vary significantly by country. The medicine has been withdrawn from the market in some countries but remains widely available in others.

Official Storage and Disposal Requirements

Analgin (Sodium Metamizole) must be stored according to regulatory specifications to ensure stability and safety.

Storage and Protection
Temperature: Store at or below the maximum temperature stated on the label, typically 25 C to 30 C.
Environment: Keep the medicine protected from light and moisture.
Child Safety: Store the product out of the sight and reach of children.

To maintain the drug's integrity, Analgin must be kept in its original package.

For disposal, unused or expired Analgin should be returned to a drug take-back program when available. It must not be discarded via wastewater (sinks or toilets). If a take-back program is unavailable, mix the medicine with an unappealing substance, seal it in a container, and place it in the trash, as directed by official guidelines.